Another study found that JNJ-40,346,527, a CSF-1R inhibitor, effectively reduces the expression of multiple genes related to EMT, stem cell markers, and resistance mechanisms in diverse CSF-1R-positive lung cancer cell lines (e.g., A549, NCI-H1299, NCI-H157, CALU-1, NCI-H1975, NCI-H358 and NCI-H4660) [146–148]. The gene discussed is CSF1R; the disease is lung cancer.